CCChristine Carrington

Christine Carrington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christine Carrington has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Telepharmacy for outpatients with cancer: An implementation evaluation of videoconsults compared to telephone consults using the CFIR 2.0

    by Marissa Ryan, Elizabeth C. Ward, Clare Burns, Christine Carrington, Katharine Cuff, Mhairi Mackinnon, Centaine L. Snoswell


  • Open Access

    A systematic review of synchronous telepharmacy service models for adult outpatients with cancer

    by Marissa Ryan, Tara Poke, Elizabeth C. Ward, Christine Carrington, Centaine L. Snoswell


  • Open Access

    Is the use of ranitidine required as a pre‐medication to prevent hypersensitivity reactions to paclitaxel?

    by Marissa Ryan, Centaine Snoswell, Christine Carrington

    The aim of this brief report was to retrospectively compare the severity and incidence of hypersensitivity reactions (HSRs) in patients who received ranitidine and patients who did not receive ranitidine, as part of their pre‐medication prior to paclitaxel. Data was collected for patients receiving paclitaxel‐containing protocols for breast, head and neck, or lung cancers in 2019 and 2020. The data included the pre‐medications administered prior to each paclitaxel dose, the total doses received and whether a HSR event occurred along with its severity. Eighty patients were reviewed receiving a total of 512 paclitaxel doses with 17 HSRs identified in 15 patients. Of the 241 doses in the ranitidine group, 11 HSRs were recorded for nine patients, compared to the 271 doses in the non‐ranitidine group where six HSRs were recorded for six patients. Most of the 512 chemotherapy doses were preceded by dexamethasone (100%) and loratadine (99.6%). Our results show that the incidence of paclitaxel‐related HSRs was not lowered with the addition of ranitidine to dexamethasone and loratadine. Future studies are warranted exploring the use of any H2‐antagonist as part of the pre‐medication regimen with paclitaxel‐containing protocols and their clinical relevance in preventing or minimising HSR incidence and severity.


  • A smartphone program to support adherence to oral chemotherapy in people with cancer: Proof‐of‐concept trial

    by Xiomara Skrabal Ross, Kate M. Gunn, Vijayaprakash Suppiah, Pandora Patterson, Terry Boyle, Christine Carrington, Shir Ley Tan, Marissa Ryan, Rohit Joshi, Ian Olver

    Aim: Nonadherence to oral chemotherapy (OC) can lead to health complications, including premature death. Mobile phones are increasingly used to deliver medication adherence interventions. However, there is limited evidence about mobile phone–based interventions to increase adherence to OC, specifically. This study explores the proof‐of‐concept of a smartphone program to support adherence to OC in people with cancer.Methods: This was a 10‐week, nonrandomized, multisite trial. The outcomes assessed were acceptability, satisfaction with the intervention, adherence to OC, knowledge about OC, and side‐effects presence and severity. The program consisted of short message service (SMS) reminders to take OC, as well as information about OC, including the management of side‐effects.Results: Twenty‐two participants (17–74 y/o, median age 60 y/o) were recruited at six hospitals. The sample included 10 different cancer diagnoses (predominance of breast cancer) and 11 OC medications. Acceptability of the intervention was high, with 95% of the enrolled participants completing postintervention measures, and 81% reporting high satisfaction with the program. The intervention was found to have no effect on supporting adherence to OC (assessed by self‐report and medication event monitoring system) in this sample. An increase in knowledge about OC was observed at postintervention (p = 0.010).Conclusions: This study demonstrated proof‐of‐concept of the smartphone program and highlighted the need for intervention and trial design‐related refinements. Future work should evaluate the effect of the program on adherence to OC with nonadherent patients.


  • Open Access

    Changing from telephone to videoconference for pre-treatment pharmacist consults in cancer services: Impacts to funding and time efficiency

    by Marissa Ryan, Christine Carrington, Elizabeth C Ward, Clare L Burns, Katharine Cuff, Mhairi Mackinnon, Centaine L Snoswell

    Introduction: This study examined the reimbursement opportunity and the time efficiency of a standard care model of unscheduled telephone consults compared to scheduled videoconference consults for obtaining pre-treatment medication histories for patients with cancer. Methods: Data related to (a) the available and the claimed activity-based funding for both models and (b) the number of contacts and the duration of each contact to complete the patient’s medication history via either unscheduled telephone or scheduled videoconference consults were collected and compared. Results: Data was collected for 86 telephone and 56 videoconference consults. The actual activity-based funding claimed for telephone consults was $0, even though $86 of activity-based funding was available for each consult. This represented a $0 reimbursement for the staff time spent conducting the telephone consults, and a missed opportunity to claim $86 per consult. Activity-based funding was claimed for all but one videoconference consult with an average of $205 received per consult, when $221 per consult was available. Videoconference consults were an average of 2.3 min shorter than telephone consults. Discussion: When compared to unscheduled telephone consults, the scheduled videoconference consults represented increased reimbursement and equivalent time efficiency for the cancer pharmacist completing pre-treatment medication histories.


  • Open Access

    Medicinal Mishap: Death from diltiazem-ibrutinib interaction

    by Nazanin Falconer, Marissa Ryan, Belinda Badman, Christine Carrington

    Beware of interactions with tyrosine kinase inhibitors.


  • Open Access

    Partnering with general practitioners to optimize survivorship for patients with lymphoma: a phase II randomized controlled trial (the GOSPEL I trial)

    by Raymond Javan Chan, Stephanie Buhagiar, Laisa Teleni, Camilla Simonsen, Jane Turner, Courtney Rawson, Nicolas H. Hart, Lee Jones, Louisa Gordon, Ria Joseph, et al.

    Background: Survival rates for lymphoma are highest amongst hematological malignancies. In 2019, it was estimated that over 6400 Australians were diagnosed with lymphoma, a group of hematological malignancies with a high 5-year survival rate of ~ 76%. There is an increased focus on the promotion of wellness in survivorship and active approaches to reducing morbidity related to treatment; however, current models of follow-up care heavily rely on hospital-based specialist-led care. Maximizing the potential of general practitioners (GPs) in the ongoing management of cancer is consistent with the national health reform principles and the Cancer Council Australia’s Optimal Care Pathways. GPs are well positioned to provide guideline-based follow-up care and are more likely to address comorbidities and psychosocial issues and promote healthy lifestyle behaviors. This study aims to test the feasibility of the GOSPEL I intervention for implementing an integrated, shared care model in which cancer center specialists and community-based GPs collaborate to provide survivorship care for patients with lymphoma. Methods: We describe a protocol for a phase II, randomized controlled trial with two parallel arms and a 1:1 allocation. Sixty patients with Hodgkin’s and non-Hodgkin’s lymphoma will be randomized to usual specialist-led follow-up care (as determined by the treating hematologists) or a shared follow-up care intervention (i.e., GOSPEL I). GOSPEL I is a nurse-enabled, pre-specified shared care pathway with follow-up responsibilities shared between cancer center specialists (i.e., hematologists and specialist cancer nurses) and GPs. Outcome measures assess feasibility as well as a range of patient-reported outcomes including health-related quality of life as measured by the Functional Assessment of Cancer Therapy—Lymphoma, patient experience of care, symptom distress, comorbidity burden, dietary intake, physical activity behaviors, financial distress/interference, and satisfaction of care. Safety indicators including hospital admission and unscheduled lymphoma clinic visits as well as process outcomes such as intervention fidelity and economic indicators will be analyzed. Discussion: This trial is designed to explore the feasibility and acceptability of a new model of shared care for lymphoma survivors. Patient-reported outcomes as well as potential barriers to implementation will be analyzed to inform a larger definitive clinical trial testing the effects and implementation of a shared care model on health-related quality of life of lymphoma survivors. Trial registration: Australia and New Zealand Clinical Trials Registry ACTRN12620000594921. Registered on 22 May 2020.


  • Open Access

    Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in breast cancer post-treatment follow-up: a study protocol for a phase II randomised controlled trial (the EMINENT trial)

    by Raymond Javan Chan, Jon Emery, Katharine Cuff, Laisa Teleni, Camilla Simonsen, Jane Turner, Monika Janda, Daniel Mckavanagh, Lee Jones, Emma McKinnell, et al.

    Background: Due to advances in early detection and cancer treatment, 5-year relative survival rates for early breast cancer surpass 90% in developed nations. There is increasing focus on promotion of wellness in survivorship and active approaches to reducing morbidity related to treatment; however, current models of follow-up care are heavily reliant on hospital-based specialist-led care. This study aims to test the feasibility of the EMINENT intervention for implementing an integrated, shared-care model involving both cancer centre specialists and community-based general practitioners for early breast cancer post-treatment follow-up. Methods: We describe a protocol for a phase II, randomised controlled trial with two parallel arms and 1:1 allocation. A total of 60 patients with early-stage breast cancer will be randomised to usual, specialist-led, follow-up care (as determined by the treating surgeons, medical oncologists, and radiation oncologists) or shared follow-up care intervention (i.e. EMINENT). EMINENT is a nurse-enabled, pre-specified shared-care pathway with follow-up responsibilities divided between cancer centre specialists (i.e. surgeons and oncologists) and general practitioners. The primary outcome is health-related quality of life as measured by the Functional Assessment of Cancer Therapy—Breast Cancer. Secondary outcomes include patient experience, acceptance, and satisfaction of care; dietary, physical activity, and sedentary behaviours; financial toxicity; adherence; health resource utilisation; and adverse events. Discussion: The trial is designed to identify the barriers to implementing a shared-care model for breast cancer survivors following treatment. Results of this study will inform a definitive trial testing the effects of shared-care model on health-related quality of life of breast cancer survivors, as well as its ability to alleviate the growing demands on the healthcare system. Trial registration: Australia and New Zealand Clinical Trials Registry ACTRN12619001594112. Registered on 19 November 2019


  • Open Access

    Implementing a Nurse-Enabled, Integrated, Shared-Care Model Involving Specialists and General Practitioners in Breast Cancer Post-Treatment Follow-Up: A Study Protocol for a Phase II Randomised Controlled Trial (The EMINENT Trial)

    by Raymond Chan, Jon Emery, Katharine Cuff, Laisa Teleni, Camilla Simonsen, Jane Turner, Monika Janda, Daniel Mckavanagh, Lee Jones, Emma McKinnell, et al.

    Background: Due to advances in early detection and cancer treatment, 5-year relative survival rates for early breast cancer surpass 90% in developed nations. There is increasing focus on promotion of wellness in survivorship and active approaches to reducing morbidity related to treatment; however, current models of follow-up care are heavily reliant on hospital-based specialist-led care. This study aims to test the feasibility of the EMINENT intervention for implementing an integrated, shared-care model involving both cancer center specialists and community-based general practitioners for early breast cancer post-treatment follow-up.Methods: We describe a protocol for a phase II, randomized controlled trial with two parallel arms and 1:1 allocation. A total of 60 patients with early stage breast cancer will be randomized to usual, specialist-led, follow-up care (as determined by the treating surgeons, medical oncologists, and radiation oncologists) or shared follow-up care intervention (i.e., EMINENT). EMINENT is a nurse-enabled, pre-specified shared-care pathway with follow-up responsibilities divided between cancer center specialists (i.e., surgeons and oncologists) and general practitioners. Primary outcome is health-related quality of life as measured by the Functional Assessment of Cancer Therapy-Breast Cancer. Secondary outcomes include patient experience, acceptance, and satisfaction of care; dietary, physical activity and sedentary behaviors; financial toxicity; adherence; health resource utilization; and adverse events.Discussion: The trial is designed to identify the barriers to implementing a shared-care model for breast cancer survivors following treatment. Results of this study will inform a definitive trial testing the effects of shared-care model on health-related quality of life of breast cancer survivors, as well as its ability to alleviate the growing demands on the healthcare system.Trial registration: Trial registration: Australia and New Zealand Clinical Trials Registry, ACTRN12619001594112). Registered 19 November 2019, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378690&isReview=true.

  • Open Access

    A consensus statement on the use of biosimilar medicines in hematology in Australia

    by Gareth P. Gregory, Christine Carrington, Chan Y. Cheah, Eliza A. Hawkes, Ian M. Irving, Jim Siderov, Stephen Opat

    Despite their availability for over a decade, the exact nature of biosimilar medicines is still poorly understood with paucity of clear treatment guidelines for their use in clinical practice in Australia. Although hematologists have had experience with biosimilars in the setting of supportive care, with the approval of the first biosimilar rituximab in hematological malignancies, it is important to revisit this topic. To inform the use of biosimilar medicines in clinical practice, we have developed a consensus statement from an Expert Panel of Australian hematologists, oncologists, and cancer pharmacists. These recommendations address the approach to use of biosimilar products in place of the corresponding reference medicine in a number of different clinical contexts. Our recommendations are based on the premise that biosimilar medicines can be considered therapeutically equivalent to their reference brand and used in a similar way to the reference product in any approved indication. We advocate for local approaches to the provision of patient information, dispensing of the intended brand and pharmacovigilance, to be developed in consultation with local hematologists and aim to improve confidence in the appropriate use of biosimilar medicines and their expected outcomes among hematologists.